Clinical trials
SMA clinical trials
Below are recruiting sma clinical trials, each written for real people, not researchers. We’re tracking 44 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03217578Recruiting
Newborn screening for spinal muscular atrophy in Taiwan
This trial offers testing for spinal muscular atrophy (SMA) to newborns. It aims to identify SMA early so families and doctors can act sooner if results suggest the condition.
Kaohsiung CityAges birth–2 weeks - NCT06322654Recruiting
Comparing two types of robotic rehab for spinal muscular atrophy
This study compares two robot-assisted rehabilitation programs to see which one helps children and young adults with spinal muscular atrophy (SMA) improve their movement and function better. You may join if you have SMA (types 1-4), are up to 21 years old, and are already receiving medication for SMA.
PoznanAges Up to 21 years - NCT07488338Recruiting
Movement and hand training for children with SMA
This study tests whether a combined program of home-based activities and hand training can help children with spinal muscular atrophy improve their movement and daily function. It is for children who can sit or walk with support and have been on stable medication for at least 6 months.
New York, New YorkAges 5–17 - NCT04174157Recruiting
Spinal muscular atrophy patient registry for OAV-101
This is a registry that collects information from people with spinal muscular atrophy (SMA) who have been treated with OAV-101. It helps researchers understand how patients do over time after this treatment.
Phoenix, ArizonaAges Any age - NCT07444476RecruitingPhase 3
Study of salanersen for spinal muscular atrophy (ages 15-60)
This trial tests a medicine called salanersen (BIIB115) to see how well it improves movement and how safe it is in people with spinal muscular atrophy (SMA). It includes those who have never taken an SMA drug or are currently on risdiplam and willing to switch.
Palo Alto, CaliforniaAges 15–60 - NCT07420777Recruiting
3D-printed aligners for treating an open bite
This study tests whether new 3D-printed shape-memory aligners can effectively fix a mild-to-moderate open bite (when front teeth don't touch when you bite down). It may be a good option if you are between 18 and 35, generally healthy, and have a mild open bite with fairly straight teeth.
Erbil, Erbil GovernorateAges 18–35 - NCT07223489Recruiting
Understanding Adult SMA Diagnosis & Treatment Experiences
This trial explores the experiences of adults with spinal muscular atrophy (SMA) in the MedStar Health System, looking at how they are diagnosed and treated, and any differences in care they may face.
Washinton, District of ColumbiaAges 18 years+ - NCT06978985Recruiting
Adult SMA research and clinical hub study
This study creates a registry and clinical hub for adults with 5q spinal muscular atrophy (SMA). It aims to track health outcomes and improve care for people living with SMA.
BirminghamAges 16 years+ - NCT06971094RecruitingPhase 3
Gene therapy for type 2 spinal muscular atrophy
This trial tests a new gene therapy called GC101 given as a one-time injection into the spinal fluid for people with type 2 spinal muscular atrophy (SMA). It may help improve motor function.
BeijingAges 2–12 - NCT05375968RecruitingPhase 2
Test blood-flow changes in POTS after meals
This Phase 2 study looks at how blood pools in the belly veins when you stand or eat, in people with POTS (postural tachycardia syndrome). The goal is to understand what’s driving symptoms like feeling nearly faint and whether this helps guide better care.
Nashville, TennesseeAges 18–50 - NCT05331937RecruitingPhase 3
TMS plus exposure therapy for severe OCD that won’t improve
This trial studies whether TMS (a brain stimulation treatment) can help people with severe OCD who have not responded well to exposure therapy. It combines brain stimulation with intensive exposure therapy to reduce obsessions and compulsions.
Amsterdam, North HollandAges 18 years+ - NCT04292574Recruiting
UK Spinal Muscular Atrophy patient registry
This trial is a registry that collects health information from people with spinal muscular atrophy (SMA). It helps researchers understand the condition better and may support future studies and treatments.
Newcastle upon TyneAges Any age - NCT07221669RecruitingPhase 3
Pre-symptomatic salanersen study for babies with SMA
This trial tests if the drug salanersen can help movement and is safe when given to babies diagnosed with spinal muscular atrophy before they show symptoms. It's for very young infants with specific genetic types of SMA.
Chicago, IllinoisAges birth–1 month - NCT07444450RecruitingPhase 3
Study of salanersen for babies with SMA previously treated with gene therapy
This study tests a new medicine called salanersen in babies who have already received gene therapy for SMA. It aims to see if adding salanersen is safe and effective.
Flower Mound, TexasAges birth–7 months - NCT04010604Recruiting
Study of spinal muscular atrophy in patients and carriers
This is a long-term observation study that follows people affected by spinal muscular atrophy (SMA), people who carry the SMA gene but have no symptoms, and families of people with SMA. It helps researchers better understand SMA and related genetic status, which can support future treatment planning.
Fuzhou, FujianAges 1 week–70 years - NCT05768048Recruiting
Study tracks SMA patients with specific gene changes
This study follows people with spinal muscular atrophy (SMA) who have a particular genetic change in the SMN1 gene. It compares long-term outcomes for those who do and do not receive disease-modifying treatments, to better understand what helps over time.
GenovaAges Any age - NCT05755451Recruiting
Study of the natural course of spinal muscular atrophy
This study observes how spinal muscular atrophy changes over time without giving an investigational treatment. It may help researchers learn what to expect in the disease and improve future care.
GenovaAges Any age - NCT05747261RecruitingPhase 1/Phase 2
Single-dose gene therapy for children with spinal muscular atrophy
This trial tests a one-time gene therapy given through a vein to add a working SMN gene in children with spinal muscular atrophy (SMA). It mainly looks at safety first, and also checks early signs that treatment helps the disease.
MinskAges Up to 8 months - NCT05954455Recruiting
Studying speech and swallowing development in children with SMA type 1
This study looks at how speech, communication, and swallowing (“bulbar function”) develop in babies and children with SMA type 1. It aims to better understand what to expect over time for children who start approved SMA treatments early.
LondonAges birth–18 years - NCT07543003Recruiting
Wearable Monitoring for Young Children With Spinal Muscular Atrophy
This study uses wearable devices (like smartwatches or activity trackers) to monitor movement and motor development in young children with spinal muscular atrophy (SMA), a rare genetic condition affecting muscle strength. The goal is to see if wearables can track disease progression and treatment response better than traditional clinic visits.
OxfordAges Up to 4 years - NCT07531719Recruiting
Risdiplam treatment study for type I and II spinal muscle atrophy
This study follows children with spinal muscular atrophy (SMA)—a genetic condition causing muscle weakness—who are being treated with a medicine called risdiplam. Researchers want to understand how well the treatment works and how it affects daily life in young patients.
CairoAges Up to 5 years - NCT07467187Recruiting
Home Ventilation with Tracheostomy in Denmark (2016–2025)
This study looks at people in Denmark who need a home ventilator through a tracheostomy. It aims to understand their care and outcomes over several years.
CopenhagenAges Any age - NCT05852418Recruiting
Registry study of devices, medicines, and care in ALS and SMA
This study collects information in a registry about assistive devices, medicines, and healthcare support for people with long-term neurological conditions like ALS and SMA. It may help researchers understand what treatments and supports are used and how they relate to patients’ needs over time.
BerlinAges 18 years+ - NCT07400198Recruiting
Walking and Bone Health Study for SMA
This study looks at walking and bone health in people with spinal muscular atrophy (SMA). It helps researchers understand how SMA affects your gait (the way you walk) and your bones, which could lead to better treatments.
New York, New YorkAges 8–50
Hear when a new SMA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sma?
- Yes. Clin2 currently lists 44 recruiting sma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.